300
Participants
Start Date
June 25, 2025
Primary Completion Date
May 30, 2027
Study Completion Date
May 30, 2027
Tezepelumab
Tezepelumab is indicated as an add-on maintenance treatment in adult and adolescent ≥12 years patients with severe uncontrolled asthma despite high-dose inhaled corticosteroids plus long-acting β-agonists
NOT_YET_RECRUITING
Research Site, Garbagnate Milanese
NOT_YET_RECRUITING
Research Site, Cittadella
RECRUITING
Research Site, Montebelluna
NOT_YET_RECRUITING
Research Site, Aosta
RECRUITING
Research Site, Avellino
NOT_YET_RECRUITING
Research Site, Bari
NOT_YET_RECRUITING
Research Site, Bergamo
NOT_YET_RECRUITING
Research Site, Brescia
NOT_YET_RECRUITING
Research Site, Cagliari
NOT_YET_RECRUITING
Research Site, Catania
NOT_YET_RECRUITING
Research Site, Catanzaro
NOT_YET_RECRUITING
Research Site, Civitanova Marche
NOT_YET_RECRUITING
Research Site, Ferrara
NOT_YET_RECRUITING
Research Site, Foggia
NOT_YET_RECRUITING
Research Site, Genova
NOT_YET_RECRUITING
Research Site, Lamezia Terme
RECRUITING
Research Site, Massa Carrara
NOT_YET_RECRUITING
Research Site, Milan
NOT_YET_RECRUITING
Research Site, Modena
NOT_YET_RECRUITING
Research Site, Napoli
NOT_YET_RECRUITING
Research Site, Orbassano (TO)
NOT_YET_RECRUITING
Research Site, Padua
NOT_YET_RECRUITING
Research Site, Reggio Calabria
NOT_YET_RECRUITING
Research Site, Reggio Emilia
NOT_YET_RECRUITING
Research Site, Roma
NOT_YET_RECRUITING
Research Site, Salerno
RECRUITING
Research Site, Sassari
NOT_YET_RECRUITING
Research Site, Torino
NOT_YET_RECRUITING
Research Site, Tradate (VA)
NOT_YET_RECRUITING
Research Site, Verona
Lead Sponsor
AstraZeneca
INDUSTRY